Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea
Purpose To assess the therapeutic effect and toxicity of intravenous colistin in the treatment of multidrug-resistant (MDR) Gram-negative bacteria in patients with severe burns. Methods The medical records of 930 patients admitted to the Burn Intensive Care Unit (ICU) at Hallym University Hangang Sa...
Gespeichert in:
| Veröffentlicht in: | Infection 2012-02, Vol.40 (1), p.27-33 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 33 |
|---|---|
| container_issue | 1 |
| container_start_page | 27 |
| container_title | Infection |
| container_volume | 40 |
| creator | Cho, Y. S. Yim, H. Yang, H. T. Hur, J. Chun, W. Kim, J. H. Lee, B. C. Seo, D. K. Kim, D. |
| description | Purpose
To assess the therapeutic effect and toxicity of intravenous colistin in the treatment of multidrug-resistant (MDR) Gram-negative bacteria in patients with severe burns.
Methods
The medical records of 930 patients admitted to the Burn Intensive Care Unit (ICU) at Hallym University Hangang Sacred Heart Hospital, Seoul, South Korea between April 2007 and December 2009 were retrospectively reviewed. Of these, the 104 patients who had received intravenous colistin treatments (104 courses) during this period were enrolled in the study. Changes in creatinine level were analyzed in three groups: all patients receiving colistin (
n
= 104), patients with undergoing continuous renal replacement therapy (CRRT group;
n
= 38), and patients not undergoing CRRT (non-CRRT group;
n
= 66).
Results
Among these patients, the burnt body surface area ranged from 5 to 96% (mean 49.7%). Thirty-five patients (33.7%) suffered inhalation injury, and CRRT was administered to 38 patients. The mean duration of colistin treatment was 14.7 (range 4–71) days. The total dose of colistin was 3,045.7 mg (range 100–13,800). The length of ICU stay was 48.9 (range 7–154) days. Forty patients (38.5%) died. The mean pre-colistin creatinine level of all patients was 1.04 mg/dL, and the mean post-colistin level was 1.34 mg/dL. The mean pre-colistin creatinine level of the CRRT group and non-CRRT group was 1.68 and 0.66 mg/dL, and the mean post-colistin level was 1.68 and 1.14 mg/dL, respectively.
Conclusions
Colistin appears to be a relatively safe and effective treatment for major burn patients with infections caused by MDR Gram-negative bacteria when no other drug is available. Additionally, we found no statistically significant impairment of creatinine levels. |
| doi_str_mv | 10.1007/s15010-011-0192-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_968170036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2591635211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-99becfa3011fc70006d920cda61260bbb39d8bb01fd30e595f88038f6fc1527f3</originalsourceid><addsrcrecordid>eNqFkctKxDAUhoMoOl4ewI0UN66q5yTTS5Yi3lBwoa5D2iZjh7YZk1QQfHjPOF5AEBchkPOdL_z8jO0jHCNAcRIwA4QUEOlInhZrbIJTIVOQhVhnExAAaYk832LbIcwBIJPTYpNtcSxliSgn7O0xmMTZZKG9GaLxuktq17UhtkNinU_ik0miNzr2NF6C_djF1ptAiKaXS6_7dDAzHdsXEvmZHtrQh4TWez0nQTX6geyxpf2P53s3xqfkxpF0l21Y3QWz93nvsMeL84ezq_T27vL67PQ2rTPEmEpZmdpqQTltXVCKvJEc6kbnFA2qqhKyKasK0DYCTCYzW5YgSpvbGjNeWLHDjlbehXfPowlR9W2oTdfpwbgxKJmXSF6R_09ygRJwWhB5-IucO4pKMQjiGXKOnCBcQbV3IXhj1cK3vfavCkEtK1SrChVFU8sK1VJ88Ckeq9403xtfnRHAV0Cg0TAz_ufnv63vCounfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>922512212</pqid></control><display><type>article</type><title>Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Cho, Y. S. ; Yim, H. ; Yang, H. T. ; Hur, J. ; Chun, W. ; Kim, J. H. ; Lee, B. C. ; Seo, D. K. ; Kim, D.</creator><creatorcontrib>Cho, Y. S. ; Yim, H. ; Yang, H. T. ; Hur, J. ; Chun, W. ; Kim, J. H. ; Lee, B. C. ; Seo, D. K. ; Kim, D.</creatorcontrib><description>Purpose
To assess the therapeutic effect and toxicity of intravenous colistin in the treatment of multidrug-resistant (MDR) Gram-negative bacteria in patients with severe burns.
Methods
The medical records of 930 patients admitted to the Burn Intensive Care Unit (ICU) at Hallym University Hangang Sacred Heart Hospital, Seoul, South Korea between April 2007 and December 2009 were retrospectively reviewed. Of these, the 104 patients who had received intravenous colistin treatments (104 courses) during this period were enrolled in the study. Changes in creatinine level were analyzed in three groups: all patients receiving colistin (
n
= 104), patients with undergoing continuous renal replacement therapy (CRRT group;
n
= 38), and patients not undergoing CRRT (non-CRRT group;
n
= 66).
Results
Among these patients, the burnt body surface area ranged from 5 to 96% (mean 49.7%). Thirty-five patients (33.7%) suffered inhalation injury, and CRRT was administered to 38 patients. The mean duration of colistin treatment was 14.7 (range 4–71) days. The total dose of colistin was 3,045.7 mg (range 100–13,800). The length of ICU stay was 48.9 (range 7–154) days. Forty patients (38.5%) died. The mean pre-colistin creatinine level of all patients was 1.04 mg/dL, and the mean post-colistin level was 1.34 mg/dL. The mean pre-colistin creatinine level of the CRRT group and non-CRRT group was 1.68 and 0.66 mg/dL, and the mean post-colistin level was 1.68 and 1.14 mg/dL, respectively.
Conclusions
Colistin appears to be a relatively safe and effective treatment for major burn patients with infections caused by MDR Gram-negative bacteria when no other drug is available. Additionally, we found no statistically significant impairment of creatinine levels.</description><identifier>ISSN: 0300-8126</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-011-0192-7</identifier><identifier>PMID: 21898119</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Acinetobacter - isolation & purification ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - microbiology ; Acinetobacter Infections - mortality ; Adult ; Aged, 80 and over ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Bacteria ; Burn Units ; Burns - blood ; Burns - drug therapy ; Burns - microbiology ; Burns - mortality ; Child ; Clinical and Epidemiological Study ; Colistin - administration & dosage ; Colistin - therapeutic use ; Creatinine - blood ; Drug Resistance, Multiple, Bacterial ; Family Medicine ; Female ; General Practice ; Humans ; Infectious Diseases ; Inhalation ; Internal Medicine ; Length of Stay ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Pseudomonas - isolation & purification ; Pseudomonas Infections - drug therapy ; Pseudomonas Infections - microbiology ; Pseudomonas Infections - mortality ; Renal Replacement Therapy ; Republic of Korea ; Retrospective Studies ; Young Adult</subject><ispartof>Infection, 2012-02, Vol.40 (1), p.27-33</ispartof><rights>Springer-Verlag 2011</rights><rights>Springer-Verlag 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-99becfa3011fc70006d920cda61260bbb39d8bb01fd30e595f88038f6fc1527f3</citedby><cites>FETCH-LOGICAL-c511t-99becfa3011fc70006d920cda61260bbb39d8bb01fd30e595f88038f6fc1527f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s15010-011-0192-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s15010-011-0192-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21898119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cho, Y. S.</creatorcontrib><creatorcontrib>Yim, H.</creatorcontrib><creatorcontrib>Yang, H. T.</creatorcontrib><creatorcontrib>Hur, J.</creatorcontrib><creatorcontrib>Chun, W.</creatorcontrib><creatorcontrib>Kim, J. H.</creatorcontrib><creatorcontrib>Lee, B. C.</creatorcontrib><creatorcontrib>Seo, D. K.</creatorcontrib><creatorcontrib>Kim, D.</creatorcontrib><title>Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea</title><title>Infection</title><addtitle>Infection</addtitle><addtitle>Infection</addtitle><description>Purpose
To assess the therapeutic effect and toxicity of intravenous colistin in the treatment of multidrug-resistant (MDR) Gram-negative bacteria in patients with severe burns.
Methods
The medical records of 930 patients admitted to the Burn Intensive Care Unit (ICU) at Hallym University Hangang Sacred Heart Hospital, Seoul, South Korea between April 2007 and December 2009 were retrospectively reviewed. Of these, the 104 patients who had received intravenous colistin treatments (104 courses) during this period were enrolled in the study. Changes in creatinine level were analyzed in three groups: all patients receiving colistin (
n
= 104), patients with undergoing continuous renal replacement therapy (CRRT group;
n
= 38), and patients not undergoing CRRT (non-CRRT group;
n
= 66).
Results
Among these patients, the burnt body surface area ranged from 5 to 96% (mean 49.7%). Thirty-five patients (33.7%) suffered inhalation injury, and CRRT was administered to 38 patients. The mean duration of colistin treatment was 14.7 (range 4–71) days. The total dose of colistin was 3,045.7 mg (range 100–13,800). The length of ICU stay was 48.9 (range 7–154) days. Forty patients (38.5%) died. The mean pre-colistin creatinine level of all patients was 1.04 mg/dL, and the mean post-colistin level was 1.34 mg/dL. The mean pre-colistin creatinine level of the CRRT group and non-CRRT group was 1.68 and 0.66 mg/dL, and the mean post-colistin level was 1.68 and 1.14 mg/dL, respectively.
Conclusions
Colistin appears to be a relatively safe and effective treatment for major burn patients with infections caused by MDR Gram-negative bacteria when no other drug is available. Additionally, we found no statistically significant impairment of creatinine levels.</description><subject>Acinetobacter - isolation & purification</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Acinetobacter Infections - mortality</subject><subject>Adult</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteria</subject><subject>Burn Units</subject><subject>Burns - blood</subject><subject>Burns - drug therapy</subject><subject>Burns - microbiology</subject><subject>Burns - mortality</subject><subject>Child</subject><subject>Clinical and Epidemiological Study</subject><subject>Colistin - administration & dosage</subject><subject>Colistin - therapeutic use</subject><subject>Creatinine - blood</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Family Medicine</subject><subject>Female</subject><subject>General Practice</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Inhalation</subject><subject>Internal Medicine</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Pseudomonas - isolation & purification</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Pseudomonas Infections - microbiology</subject><subject>Pseudomonas Infections - mortality</subject><subject>Renal Replacement Therapy</subject><subject>Republic of Korea</subject><subject>Retrospective Studies</subject><subject>Young Adult</subject><issn>0300-8126</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkctKxDAUhoMoOl4ewI0UN66q5yTTS5Yi3lBwoa5D2iZjh7YZk1QQfHjPOF5AEBchkPOdL_z8jO0jHCNAcRIwA4QUEOlInhZrbIJTIVOQhVhnExAAaYk832LbIcwBIJPTYpNtcSxliSgn7O0xmMTZZKG9GaLxuktq17UhtkNinU_ik0miNzr2NF6C_djF1ptAiKaXS6_7dDAzHdsXEvmZHtrQh4TWez0nQTX6geyxpf2P53s3xqfkxpF0l21Y3QWz93nvsMeL84ezq_T27vL67PQ2rTPEmEpZmdpqQTltXVCKvJEc6kbnFA2qqhKyKasK0DYCTCYzW5YgSpvbGjNeWLHDjlbehXfPowlR9W2oTdfpwbgxKJmXSF6R_09ygRJwWhB5-IucO4pKMQjiGXKOnCBcQbV3IXhj1cK3vfavCkEtK1SrChVFU8sK1VJ88Ckeq9403xtfnRHAV0Cg0TAz_ufnv63vCounfw</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Cho, Y. S.</creator><creator>Yim, H.</creator><creator>Yang, H. T.</creator><creator>Hur, J.</creator><creator>Chun, W.</creator><creator>Kim, J. H.</creator><creator>Lee, B. C.</creator><creator>Seo, D. K.</creator><creator>Kim, D.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea</title><author>Cho, Y. S. ; Yim, H. ; Yang, H. T. ; Hur, J. ; Chun, W. ; Kim, J. H. ; Lee, B. C. ; Seo, D. K. ; Kim, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-99becfa3011fc70006d920cda61260bbb39d8bb01fd30e595f88038f6fc1527f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acinetobacter - isolation & purification</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Acinetobacter Infections - mortality</topic><topic>Adult</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteria</topic><topic>Burn Units</topic><topic>Burns - blood</topic><topic>Burns - drug therapy</topic><topic>Burns - microbiology</topic><topic>Burns - mortality</topic><topic>Child</topic><topic>Clinical and Epidemiological Study</topic><topic>Colistin - administration & dosage</topic><topic>Colistin - therapeutic use</topic><topic>Creatinine - blood</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Family Medicine</topic><topic>Female</topic><topic>General Practice</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Inhalation</topic><topic>Internal Medicine</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Pseudomonas - isolation & purification</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Pseudomonas Infections - microbiology</topic><topic>Pseudomonas Infections - mortality</topic><topic>Renal Replacement Therapy</topic><topic>Republic of Korea</topic><topic>Retrospective Studies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cho, Y. S.</creatorcontrib><creatorcontrib>Yim, H.</creatorcontrib><creatorcontrib>Yang, H. T.</creatorcontrib><creatorcontrib>Hur, J.</creatorcontrib><creatorcontrib>Chun, W.</creatorcontrib><creatorcontrib>Kim, J. H.</creatorcontrib><creatorcontrib>Lee, B. C.</creatorcontrib><creatorcontrib>Seo, D. K.</creatorcontrib><creatorcontrib>Kim, D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cho, Y. S.</au><au>Yim, H.</au><au>Yang, H. T.</au><au>Hur, J.</au><au>Chun, W.</au><au>Kim, J. H.</au><au>Lee, B. C.</au><au>Seo, D. K.</au><au>Kim, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea</atitle><jtitle>Infection</jtitle><stitle>Infection</stitle><addtitle>Infection</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>40</volume><issue>1</issue><spage>27</spage><epage>33</epage><pages>27-33</pages><issn>0300-8126</issn><eissn>1439-0973</eissn><abstract>Purpose
To assess the therapeutic effect and toxicity of intravenous colistin in the treatment of multidrug-resistant (MDR) Gram-negative bacteria in patients with severe burns.
Methods
The medical records of 930 patients admitted to the Burn Intensive Care Unit (ICU) at Hallym University Hangang Sacred Heart Hospital, Seoul, South Korea between April 2007 and December 2009 were retrospectively reviewed. Of these, the 104 patients who had received intravenous colistin treatments (104 courses) during this period were enrolled in the study. Changes in creatinine level were analyzed in three groups: all patients receiving colistin (
n
= 104), patients with undergoing continuous renal replacement therapy (CRRT group;
n
= 38), and patients not undergoing CRRT (non-CRRT group;
n
= 66).
Results
Among these patients, the burnt body surface area ranged from 5 to 96% (mean 49.7%). Thirty-five patients (33.7%) suffered inhalation injury, and CRRT was administered to 38 patients. The mean duration of colistin treatment was 14.7 (range 4–71) days. The total dose of colistin was 3,045.7 mg (range 100–13,800). The length of ICU stay was 48.9 (range 7–154) days. Forty patients (38.5%) died. The mean pre-colistin creatinine level of all patients was 1.04 mg/dL, and the mean post-colistin level was 1.34 mg/dL. The mean pre-colistin creatinine level of the CRRT group and non-CRRT group was 1.68 and 0.66 mg/dL, and the mean post-colistin level was 1.68 and 1.14 mg/dL, respectively.
Conclusions
Colistin appears to be a relatively safe and effective treatment for major burn patients with infections caused by MDR Gram-negative bacteria when no other drug is available. Additionally, we found no statistically significant impairment of creatinine levels.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>21898119</pmid><doi>10.1007/s15010-011-0192-7</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8126 |
| ispartof | Infection, 2012-02, Vol.40 (1), p.27-33 |
| issn | 0300-8126 1439-0973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_968170036 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acinetobacter - isolation & purification Acinetobacter Infections - drug therapy Acinetobacter Infections - microbiology Acinetobacter Infections - mortality Adult Aged, 80 and over Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Bacteria Burn Units Burns - blood Burns - drug therapy Burns - microbiology Burns - mortality Child Clinical and Epidemiological Study Colistin - administration & dosage Colistin - therapeutic use Creatinine - blood Drug Resistance, Multiple, Bacterial Family Medicine Female General Practice Humans Infectious Diseases Inhalation Internal Medicine Length of Stay Male Medicine Medicine & Public Health Middle Aged Pseudomonas - isolation & purification Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology Pseudomonas Infections - mortality Renal Replacement Therapy Republic of Korea Retrospective Studies Young Adult |
| title | Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T20%3A33%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20parenteral%20colistin%20for%20the%20treatment%20of%20multiresistant%20Gram-negative%20organisms%20in%20major%20burn%20patients%20in%20South%20Korea&rft.jtitle=Infection&rft.au=Cho,%20Y.%20S.&rft.date=2012-02-01&rft.volume=40&rft.issue=1&rft.spage=27&rft.epage=33&rft.pages=27-33&rft.issn=0300-8126&rft.eissn=1439-0973&rft_id=info:doi/10.1007/s15010-011-0192-7&rft_dat=%3Cproquest_cross%3E2591635211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=922512212&rft_id=info:pmid/21898119&rfr_iscdi=true |